289 related articles for article (PubMed ID: 9779706)
1. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
Jaeckle KA; Eyre HJ; Townsend JJ; Schulman S; Knudson HM; Belanich M; Yarosh DB; Bearman SI; Giroux DJ; Schold SC
J Clin Oncol; 1998 Oct; 16(10):3310-5. PubMed ID: 9779706
[TBL] [Abstract][Full Text] [Related]
2. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
[TBL] [Abstract][Full Text] [Related]
3. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
Pollack IF; Hamilton RL; Sobol RW; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL
J Clin Oncol; 2006 Jul; 24(21):3431-7. PubMed ID: 16849758
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
5. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Esteller M; Garcia-Foncillas J; Andion E; Goodman SN; Hidalgo OF; Vanaclocha V; Baylin SB; Herman JG
N Engl J Med; 2000 Nov; 343(19):1350-4. PubMed ID: 11070098
[TBL] [Abstract][Full Text] [Related]
9. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.
Silber JR; Blank A; Bobola MS; Ghatan S; Kolstoe DD; Berger MS
Clin Cancer Res; 1999 Apr; 5(4):807-14. PubMed ID: 10213216
[TBL] [Abstract][Full Text] [Related]
10. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
11. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
12. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
14. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
[TBL] [Abstract][Full Text] [Related]
15. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Balaña C; Ramirez JL; Taron M; Roussos Y; Ariza A; Ballester R; Sarries C; Mendez P; Sanchez JJ; Rosell R
Clin Cancer Res; 2003 Apr; 9(4):1461-8. PubMed ID: 12684420
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Chen ZP; Pan J; Huang Q; Sun ZF; Zhou LY; Wang AD
J Neurooncol; 2001 Jan; 51(1):19-24. PubMed ID: 11349876
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma.
Miyazaki M; Nishihara H; Terasaka S; Kobayashi H; Yamaguchi S; Ito T; Kamoshima Y; Fujimoto S; Kaneko S; Katoh M; Ishii N; Mohri H; Tanino M; Kimura T; Tanaka S
Neuropathology; 2014 Jun; 34(3):268-76. PubMed ID: 24397721
[TBL] [Abstract][Full Text] [Related]
18. Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Lee SM; Reid H; Elder RH; Thatcher N; Margison GP
Carcinogenesis; 1996 Apr; 17(4):637-41. PubMed ID: 8625471
[TBL] [Abstract][Full Text] [Related]
19. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
20. Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines.
Chen ZP; Malapetsa A; McQuillan A; Marcantonio D; Bello V; Mohr G; Remack J; Brent TP; Panasci LC
Mol Pharmacol; 1997 Nov; 52(5):815-20. PubMed ID: 9351972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
